Moderna’s (MRNA) Market Perform Rating Reiterated at William Blair

William Blair restated their market perform rating on shares of Moderna (NASDAQ:MRNA) in a research report report published on Thursday morning,RTT News reports.

Other equities research analysts also recently issued reports about the stock. UBS Group decreased their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Citigroup assumed coverage on Moderna in a research report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price objective on the stock. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Finally, Bank of America reduced their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average target price of $58.70.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $24.72 on Thursday. The firm has a market capitalization of $9.56 billion, a PE ratio of -2.66 and a beta of 2.23. Moderna has a 12 month low of $23.15 and a 12 month high of $170.47. The business has a 50-day moving average of $30.84 and a two-hundred day moving average of $39.64.

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently modified their holdings of MRNA. Norges Bank bought a new stake in shares of Moderna during the 4th quarter valued at about $163,833,000. Voloridge Investment Management LLC boosted its stake in Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after acquiring an additional 1,996,003 shares during the period. FMR LLC grew its holdings in shares of Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock valued at $776,075,000 after purchasing an additional 1,282,469 shares during the last quarter. Pictet Asset Management Holding SA raised its position in shares of Moderna by 170.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock worth $73,447,000 after purchasing an additional 1,113,455 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company’s stock worth $208,169,000 after purchasing an additional 979,858 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.